Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5416072 | 1.00 | CYP1B1 (0.49) | CYP1B1CYP1A2CYP2C9CYP2C19TRPA1 | |
| SCHEMBL5416078 | 1.00 | CYP1B1 (0.49) | CYP1B1CYP1A2CYP2C9CYP2C19TRPA1 | |
| SCHEMBL5404937 | 1.00 | CYP1B1 (0.49) | CYP1B1CYP1A2CYP2C9CYP2C19TRPA1 | |
| SCHEMBL5404942 | 1.00 | CYP1B1 (0.49) | CYP1B1CYP1A2CYP2C9CYP2C19TRPA1 | |
| SCHEMBL17933679 | 0.82 | CYP1B1 (0.49) | CYP1B1CYP1A2CYP2C9CYP2C19TRPA1 | |
| SCHEMBL16513375 | 0.82 | CYP1B1 (0.49) | CYP1B1CYP1A2CYP2C9CYP2C19TRPA1 | |
| SCHEMBL21598051 | 0.81 | CYP1A2 (0.54) | CYP1B1CYP1A2CYP2C9CYP2C19TRPA1 | |
| SCHEMBL30657539 | 0.80 | CYP1B1 (0.62) | CYP1B1CYP1A2CYP2C9CYP2C19TRPA1 | |
| SCHEMBL8247166 | 0.80 | CYP1B1 (0.62) | CYP1B1CYP1A2CYP2C9CYP2C19TRPA1 | |
| SCHEMBL5413443 | 0.78 | CYP1B1 (0.46) | CYP1B1CYP1A2CYP2C9CYP2C19TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | CYP1B1 921/4885CYP1A2 2102/4885CYP2C9 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.